SCHEMBL25035336

SCHEMBL25035336

Cc1nc(NS(=O)(=O)c2ccccc2Cl)ccc1-c1nc2cnc(N)nc2n(C(C)C)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.41
MTOR P42345 3/20 0.37
RORC P51449 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
HSD11B1 P28845 1/20 0.34
ERN1 O75460 2/20 0.34
EDNRA P25101 2/20 0.34
EGFR P00533 1/20 0.34
FGFR1 P11362 1/20 0.34
SRC P12931 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR4 P22455 1/20 0.34
FGFR3 P22607 1/20 0.34
PIK3CD O00329 2/20 0.34
PIK3CA P42336 2/20 0.34
PIK3CB P42338 2/20 0.34
PIK3CG P48736 2/20 0.34
SLC40A1 Q9NP59 1/20 0.33
ALOX5AP P20292 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25034228 0.91 FEN1 (0.39) MTORRORCEDNRAPIK3CAALOX5AP
SCHEMBL25034113 0.90 MTOR (0.42) PKMMTORRORCPIK3CDPIK3CA
SCHEMBL25034241 0.89 ERN1 (0.36) MTORRORCERN1PIK3CDPIK3CA
SCHEMBL25035544 0.86 MTOR (0.42) PKMMTORRORCLMNAGAA
SCHEMBL25035541 0.86 EGFR (0.42) PKMMTORLMNAGAAEGFR
SCHEMBL22200424 0.82 MTOR (0.37) MTORRORCEGFRFGFR1SRC
SCHEMBL22191262 0.82 ERN1 (0.48) PKMERN1FGFR1
SCHEMBL22200509 0.82 ERN1 (0.48) PKMERN1FGFR1
SCHEMBL29356296 0.82 ERN1 (0.48) PKMERN1FGFR1
SCHEMBL25035440 0.79 ERN1 (0.48) ERN1PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD PKM 44/4885MTOR 487/4885RORC 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.